Skip to main content

Table 2 Echocardiographic data and force-frequency relationship during dobutamine echo

From: The pressure/volume relationship during dobutamine stress echocardiography in transplanted heart: comparison with quality of life and coronary anatomy

Left Ventricular EDV (ml) 108 ± 28
Left Ventricular ESV rest (ml/m2) 23 ± 8
Left Ventricular ESV peak (ml/m2) 11 ± 6
Systolic Pressure rest (mmHg) 127 ± 13
Systolic Pressure peak (mmHg) 160 ± 27
SP/ESV index (rest) 6.22 ± 2.53
SP/ESV index (peak) 17.03 ± 7.88
ESPVR slope (χ 10-2) 21.1 ± 7.3
Δ peak – rest (mmHg/ml) 10.85 ± 6.9
Heart rate rest (b.p.m.) 82 ± 6
Heart rate peak (b.p.m.) 129 ± 15
Left Ventricular Ejection fraction (rest, %) 59 ± 8
Left Ventricular Ejection fraction (peak, %) 72 ± 9
Double product (rest) 10437 ± 1396
Double product (peak) 20838 ± 3481
Ischaemia during Dobutamine, n (%) 3 (12%)
Flat-biphasic ESPVR during Dobutamine, n (%) 4 (16%)
Critical Heart Rate (b.p.m.) 123 ± 17
Dobutamine dose 40 μg, n (%) 22 (88%)
Dobutamine dose 30 μg, n (%) 3 (12%)
On therapy at the time of stress:  
Everolimus 10 (40%)
Tacrolimus 5 (20%)
Cyclosporine 22 (88%)
Mycophenolate mofetil 14 (56%)
Cortisone 3 (12%)
Ca-Channel Blocker 6 (24%)
Nitrates 3 (12%)
B-Blocker 19 (76%)
Diuretics 12 (48%)
Acetyl salicylic acid 23 (92%)
Amiodarone 1 (4%)
ACE-I 13 (52%)
ARBs 2 (8%)
Statins 23 (92%)
  1. ACE-I: angiotensin converting enzyme inhibitor; ARBS: Angiotensin II Receptor Blockers; EDV: end diastolic volume; ESPVR: end-systolic pressure/volume ratio; ESV: end systolic volume; SP, systolic pressure.